Noel Gerard McElvaney

This study generates glycoengineered recombinant alpha1-antitrypsin with in vitro and in vivo activities comparable to plasma-derived A1AT, offering a sustainable therapeutic alternative.

The paper uses population genomics to trace the evolution and environmental acquisition of drug-resistant Aspergillus fumigatus, finding evidence of resistant isolates transmitted from the environment to patients.